[Which should be indicated for patients with ACS, DES or BMS?].
The effectiveness of the use of drug-eluting stent (DES) in the treatment of ST-elevation myocardial infarction (STEMI), a representative condition of acute coronary syndrome, is still unknown. In this article, data of registry, randomized, and meta-analyses studies were reviewed. DES showed a consistent trend toward decreasing the risk of repeat revascularization without increasing the incidence of death, recurrent myocardial infarction, and stent thrombosis as compared to BMS. The findings concerning the use of DES in patients with STEMI are that; (1) its short-term effect of reducing the restenosis and repeat revascularization rates is evident; (2) no randomized studies have demonstrated the usefulness of DES in the prevention of death and recurrent myocardial infarction; (3) no randomized or meta-analyses studies have shown results sufficient to eliminate long-term safety concerns; and most importantly, (4) there are no data clearly indicating safety concerns.